Patents Assigned to Glaxo Group Limited
  • MODIFIED PROTEINS AND PEPTIDES
    Publication number: 20140227259
    Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
    Type: Application
    Filed: August 13, 2012
    Publication date: August 14, 2014
    Applicant: Glaxo Group Limited
    Inventors: Claire Ashman, Mary Birchler, Rudolf M.T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • FORMULATION FOR RETINOID-CONTAINING SOFT GELATIN CAPSULES
    Publication number: 20140205661
    Abstract: A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.
    Type: Application
    Filed: February 27, 2014
    Publication date: July 24, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventors: Günter DITZINGER, Bernhard GABRIEL, Anne-Hortense SCHMITT-HOFFMANN, Lutz WEVELSIEP
  • ANTIGEN BINDING CONSTRUCTS
    Publication number: 20140205604
    Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD). diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs.
    Type: Application
    Filed: July 25, 2012
    Publication date: July 24, 2014
    Applicant: Glaxo Group Limited
    Inventors: Claire Ashman, Ian Richard Catchpole, Zoe Hughes-Thomas, Alan Peter Lewis, Michael Steward
  • Method for inhibiting binding to B-cell receptor
    Patent number: 8784814
    Abstract: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprises: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i).
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 22, 2014
    Assignee: Glaxo Group Limited
    Inventors: Stuart Neville Farrow, Allard Kaptein, Jeremy David Alistair Kitson, Alison J. Winder
  • NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE
    Publication number: 20140200218
    Abstract: Disclosed are crystalline forms of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione benzenesulfonate salt and pharmaceutical compositions thereof. Also disclosed are processes for the preparation the above compounds and methods for use thereof.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: Glaxo Group Limited
    Inventors: Richard Bellingham, Andrew Mark Buswell, Victoria Ironmonger, Michael Urquhart
  • Compounds
    Patent number: 8778939
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: July 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Paula Louise Nichols, Andrew John Eatherton, Paul Bamborough, Karamjit Singh Jandu, Oliver James Philps, Daniele Andreotti
  • 3-amino-pyrazole derivatives useful against tuberculosis
    Patent number: 8779153
    Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: July 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Julia Castro Pichel, Raquel Fernandez Menendez, Esther Pilar Fernandez Velando, Silvia Gonzalez Del Valle, Araceli Mallo-Rubio
  • Drug fusions and conjugates
    Patent number: 8779103
    Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: July 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider
  • Sheet driver for use in a drug dispenser
    Patent number: 8776788
    Abstract: A sheet driver for use in a drug dispenser where the sheet driver includes a shaft with a shaft cavity co-axial with a rotational axis of the shaft and a hub that defines a hub aperture, where within the shaft cavity there is an indicator pin having a side member and an indicator pin head that may project through the hub aperture, where within the shaft cavity there is a spring for biasing said indicator pin out of the shaft cavity, and where an engagement member may selectively engage said side member of the indicator pin to prevent movement of the engagement member upon the occurrence of an fault condition of the sheet driver.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: July 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Michael Birsha Davies, Robert William Tansley
  • DRUG FUSIONS AND CONJUGATES
    Publication number: 20140193407
    Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
    Type: Application
    Filed: December 6, 2013
    Publication date: July 10, 2014
    Applicant: Glaxo Group Limited
    Inventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider, Bruce J. Hamilton
  • Pharmaceutical formulation
    Patent number: 8772303
    Abstract: The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: July 8, 2014
    Assignee: Glaxo Group Limited
    Inventor: Dirk Marinus Johannes Van Schie
  • METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES
    Publication number: 20140187750
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: Glaxo Group Limited
    Inventors: Carolyn ENEVER, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson
  • 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS
    Publication number: 20140179715
    Abstract: Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Application
    Filed: July 25, 2012
    Publication date: June 26, 2014
    Applicant: Glaxo Group Limited
    Inventors: Zehong Wan, Kai Long, Yingxia Sang, Xiaobo Su
  • Process for preparing pyrano—[2,3-C]pyridine derivatives
    Patent number: 8759523
    Abstract: The present invention relates to a process comprising the step of dehydrating a compound of Formula (I): with a suitable dehydrating reagent to form a compound of Formula (II): wherein R1-R7 are as defined herein. Compounds of Formula (II) have shown promise as intermediates to compounds useful for treating bacterial infections.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: June 24, 2014
    Assignee: Glaxo Group Limited
    Inventors: Joseph Sisko, Douglas Mans, Hao Yin
  • N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
    Patent number: 8754101
    Abstract: A compound of formula (I) wherein X represents a H atom, or a CH2OH group, Y represents a H atom, or a CH2OH group, but X and Y are not both CH2OH groups and Ar is selected from or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: June 17, 2014
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Gianpaolo Bravi, Aurelie Cecile Champigny, Diane Mary Coe, Deborah Needham, Daniel Terence Tape
  • Fluid dispensing device
    Patent number: 8752543
    Abstract: A fluid dispensing device for dispensing a fluid having a viscosity of from 10 to 2000 mPas at 25° C., the dispensing device having at least one finger-operable lever pivotably moveable into the housing transversely with respect to the longitudinal axis of the fluid discharge device, to apply a force to an actuating member connected to the neck of a container, the device having a pre-load to prevent pivoting until a pre-determined force is applied, wherein the actuating member and the lever have surfaces which slidingly interact, wherein the pre-load is formed by one of the surfaces of the actuating member or the lever having a dual-gradient profile.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: June 17, 2014
    Assignee: Glaxo Group Limited
    Inventors: Michael Birsha Davies, Mark Graham Hedley, Margot Jean Jones
  • MEDICAMENT DISPENSER
    Publication number: 20140158704
    Abstract: There is provided a medicament dispenser for use with plural elongate form medicament carriers, each having multiple distinct medicament dose portions carried thereby, the dispenser having a dispensing mechanism for dispensing the distinct medicament dose portions carried by each of the plural medicament carriers. The mechanism comprises a receiving station for receiving each of the plural medicament carriers; a release for releasing a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by the receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said a release; and an indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers.
    Type: Application
    Filed: August 19, 2013
    Publication date: June 12, 2014
    Applicant: Glaxo Group Limited
    Inventors: Gregor John McLennan Anderson, Stanley George Bonney, Michael Birsha Davies, Daniel Thomas Lintell, Alan Anthony Wilson
  • Medicament dispenser
    Patent number: 8746242
    Abstract: A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions, said medicament dispenser comprising (a) a dispensing mechanism actuable for dispensing the distinct medicament portions carried by the at least one medicament carrier; (b) a mouthpiece; and (c) a cover for the mouthpiece, the cover being movably mounted to the dispenser for sequential movement from a first position, in which the mouthpiece is covered, to a second position, in which the mouthpiece is at least part-uncovered, to a third position in which the mouthpiece is uncovered; wherein the cover is adapted to couple with the dispensing mechanism such that movement of the cover from the second position to the third position, but not the first position to the second position, results in actuation of the dispensing mechanism.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: June 10, 2014
    Assignee: Glaxo Group Limited
    Inventors: Hugh Alexander Connell, Stephen James Harvey, Robert William Tansley
  • Toothbrush
    Patent number: D706034
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: June 3, 2014
    Assignee: Glaxo Group Limited
    Inventors: Marcus Blachford, Alex Brian, Charles Drury, Rhodri Jones, Peter Kay, William Knight
  • Toothbrush
    Patent number: D706541
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: June 10, 2014
    Assignee: Glaxo Group Limited
    Inventors: Marcus Blachford, Alex Brian, Charles Drury, Peter Kay, Andrew Mitchell